The biosafety of gene therapy products remains a key hurdle to clinical application, with the immunogenicity of viral vectors being a significant concern. Vadim Pospelov’s latest research takes a step forward by using a mini-pig model—an excellent system due to its physiological similarity to humans—to evaluate the safety of the chimeric adenoviral vector Ad5/35F-GFP.
🔬 Key Findings:
In vitro and in vivo studies show reduced pro-inflammatory responses and cytokine production.
Clinical and laboratory assessments revealed no adverse effects post-administration.
Immune tolerance to Ad5/35F-GFP in mini-pigs was confirmed through transcriptome and secretome analyses.
💡What This Means:
These results highlight Ad5/35F-GFP’s potential as a safe and effective vector for gene therapy, paving the way for its clinical use. This study provides valuable insights into vector-host interactions and strengthens the foundation for the future of precision medicine.
Read full article here: https://www.mdpi.com/2227-9059/12/11/2568
